DominicWancheungLaiMD

Oncology • Washington, DC

Physician

Join to view full profile

Dr. Lai is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lai's full profile

Already have an account?

Office
3800 Reservoir Rd Nw
Washington, DC 20007
Phone+1 626-348-1181

Education & Training

NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2009 - 2012
UCLA-VA Greater Los AngelesResidency, Internal Medicine, 2005 - 2008
Albert Einstein College of MedicineClass of 2005

Certifications & Licensure

CA State Medical License 2007 - 2026
DC State Medical License 2014 - 2016
NY State Medical License 2009 - 2012
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors Start of enrollment: 2010 Oct 01
Completed
Phase 1
A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors Start of enrollment: 2014 Oct 13
Completed
Phase 1
A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer Start of enrollment: 2014 Oct 15
Completed
Phase 1
A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors Start of enrollment: 2016 Nov 18
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

22 citations
First-in-human phase I study of ABBV-085, an antibody–drug conjugate targeting LRRC15, in sarcomas and other advanced solid tumors
George D. Demetri, Jason J. Luke, Antoine Hollebecque, John D. Powderly, Alexander I. Spira
Clinical Cancer Research. 2021-04-05
33 citations
Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors
David M. Hyman, Naiyer A. Rizvi, Ronald B. Natale, Deborah K. Armstrong, Michael J. Birrer
Clinical Cancer Research. 2018-06-15
60 citations
Obesity is a significant risk factor for prostate cancer at the time of biopsy.
Stephen J. Freedland, Joanne Wen, Melanie Wuerstle, Amy S. Shah, Dominic W Lai
Urology. 2008-11-01